Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144535 | PMC |
http://dx.doi.org/10.4103/0972-5229.194010 | DOI Listing |
Hum Vaccin Immunother
December 2024
Diabetes Center, Humanitas Gavazzeni Institute, Bergamo, Italy.
Purpose: To overview the recent literature regarding the relationship between COVID-19 vaccines and glycemic control.
Methods: Data were extracted from text and tables of all available articles published up to September 2023 in PubMed Database describing glucose homeostasis data in subjects exposed to COVID-19 vaccines, focusing on patients with diabetes mellitus (DM).
Results: It is debated if the immune system impairment observed in diabetic patients makes them susceptible to lower efficacy of vaccines, but evidence suggests a possible improvement in immune response in those with good glycemic control.
Postepy Kardiol Interwencyjnej
September 2021
Department of Cardiac and Vascular Diseases, John Paul II Hospital in Krakow, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
Stress, a disruption of homeostasis, is an unavoidable part of everyday life. In medical procedures, stress profoundly affects both operators and patients. Although the stress reaction has evolved to aid survival of physical trauma, it may also be harmful, by aggravating the baseline medical condition and/or creating new stress-related medical problems.
View Article and Find Full Text PDFIndian J Crit Care Med
November 2016
Department of Neurology, Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra, India.
Over the past years there has been a significant decrease in mortality and morbidity in patients suffering from severe burns due to improved burn wound management and approaches in critical care. Survival is no longer the exception, but unfortunately death still occurs. One of the key elements concerning state-of-the-art burn care is blood glucose control and insulin therapy; it is well known that burn-induced hyperglycaemia is associated with adverse clinical outcomes.
View Article and Find Full Text PDFEndocr Relat Cancer
October 2012
Laboratory of Experimental Medicine and Endocrinology, Catholic University of Leuven, Leuven, Belgium.
The new incretin-based therapies, dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon like peptide 1 (GLP1) receptor agonists are widely used for the treatment of type 2 diabetes because of their glucose-lowering capacity with low risk of hypoglycemia. As they are weight neutral or induce weight loss in this mostly overweight population, they are popular among clinicians and patients alike. Nonetheless, concerns have been raised about GLP1's trophic effects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!